Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Molecular Profile | BRAF V600E MAP2K1 H119P |
| Therapy | CI-1040 |
| Indication/Tumor Type | melanoma |
| Response Type | resistant |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|---|---|---|---|---|---|---|
| BRAF V600E MAP2K1 H119P | melanoma | resistant | CI-1040 | Preclinical - Cell culture | Actionable | In a preclinical study, expression of MAP2K1 H119P in melanoma cells harboring BRAF V600E conferred resistance to CI-1040 (PD184352) treatment in culture (PMID: 19915144). | 19915144 |
| PubMed Id | Reference Title | Details |
|---|---|---|
| (19915144) | MEK1 mutations confer resistance to MEK and B-RAF inhibition. | Full reference... |